Cellens

Bringing clarity and precision to cancer diagnostics through mechanobiology and machine learning

Cellens, a startup co-founded by Jean Phuong Pham and fellow Engineering graduate students with Professor Igor Sokolov, explores the physical properties of cancer cells. The company develops technologies to study how cancer cells differ mechanically from healthy cells, potentially aiding early detection and treatment. Pham, now CEO, pitched the venture in 2025 at a Springboard Enterprise accelerator event.

Apr 2026Tufts NowNews article

Cellens raises **$6.5 million** to develop a bladder cancer diagnostic test combining **AI and mechanobiology**. The test aims to improve detection and monitoring for a disease affecting **83,190 new US patients annually** and **800,000 survivors**. The funding supports further research into non-invasive, precision-based approaches for bladder cancer management.

Dec 2025Today's Clinical LabNews article

LabCorp invests in a startup developing bladder cancer diagnostics after promising early clinical results. The company’s tests were validated at Harvard’s Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. This $6.5 million seed round builds on the clinical data supporting its diagnostic approach.

Dec 2025Medical Device and Diagnostic IndustryNews article

Cellens, Inc. secures **$6.5 million** in funding to develop **BioFeel™**, an AI-powered mechanobiology platform designed for **non-invasive bladder cancer detection**. The platform leverages mechanobiological signals to identify cancerous cells without traditional biopsies. This funding will accelerate research and clinical validation of the technology, aiming to improve early diagnosis and patient outcomes.

Dec 2025EIN PresswireNews article